After a decade of development, a Kansas City-based pharmaceutical company is on the brink of submitting its ADHD medication ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision ...

The breakome is a new layer in the multiomics landscape—alongside the genome, transcriptome, proteome, and interactome. While it hasn’t traditionally been included among these other omics, we consider ...

When surgeons repair tissues, they're currently limited to mechanical solutions such as sutures and staples, which can cause their own damage, or meshes and glues that may not adequately bond with ...

Advances in instruments and tools, as well as focused collaborations, improve accuracy and extend the range of applications.

Corcept revised its full-year 2025 revenue guidance to $850-900 million, with the midpoint of $875 million falling below the consensus estimate of $899 million. The company’s stock declined following ...

The court should adopt a narrow view of the Mann Act, the legal team states in a new filing, calling its application in Sean ...

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second quarter of 2025 and recent weeks include ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United ...

When surgeons repair tissues, they're currently limited to mechanical solutions like sutures and staples, which can cause their own damage, or meshes ...